Search - tctmd.com

Displaying 261 - 280 of 426

Sort: Relevancy | Date

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

News Daily News

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

Michael O'Riordan

August 08, 2017

Elevated Cardiovascular Risk May Linger for Several Years After a Severe Infection

News Daily News

Elevated Cardiovascular Risk May Linger for Several Years After a Severe Infection

August 02, 2017

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

News Daily News

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Michael O'Riordan

August 01, 2017

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

News Daily News

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

July 24, 2017

Cardiogenic Shock Remains a Deadly Complication of Acute MI No Matter When It Develops

News Daily News

Cardiogenic Shock Remains a Deadly Complication of Acute MI No Matter When It Develops

June 09, 2017

DANAMI3-DEFER Substudy Affirms Lack of Benefit for Routinely Deferring Stenting in STEMI

News Daily News

DANAMI3-DEFER Substudy Affirms Lack of Benefit for Routinely Deferring Stenting in STEMI

June 05, 2017

Thirty-Day Readmission in Acute MI Not Linked With Hospital Care or Clinical Outcomes

News Daily News

Thirty-Day Readmission in Acute MI Not Linked With Hospital Care or Clinical Outcomes

Michael O'Riordan

April 27, 2017

HEART Pathway as Safe as Usual Care for Chest Pain in the Emergency Department

News Daily News

HEART Pathway as Safe as Usual Care for Chest Pain in the Emergency Department

April 25, 2017

One in Five Acute MI Patients Drop Statins Within 2 Years

News Daily News

One in Five Acute MI Patients Drop Statins Within 2 Years

Michael O'Riordan

April 20, 2017

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

News Daily News

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

Michael O'Riordan

April 18, 2017

Rapid Rule-Out Strategy with High-Sensitivity Troponin Shows Promise Ahead of US Commercial Availability of Test

News Daily News

Rapid Rule-Out Strategy With High-Sensitivity Troponin Shows Promise Ahead of US Commercial Availability of Test

April 17, 2017

Running a Risk: Marathon Cities See Treatment Delays, More Cardiac Deaths Among Non-Race Participants

News Daily News

Running a Risk: Marathon Cities See Treatment Delays, More Cardiac Deaths Among Non-Race Participants

April 13, 2017

ICTUS: No Benefit at 10 Years With Early Invasive Strategy in NSTE ACS Patients

News Daily News

ICTUS: No Benefit at 10 Years With Early Invasive Strategy in NSTE ACS Patients

Michael O'Riordan

April 11, 2017

FFR-Guided Complete Revascularization Tops PCI of Culprit Artery Alone in Acute STEMI

News Conference News ACC 2017

FFR-Guided Complete Revascularization Tops PCI of Culprit Artery Alone in Acute STEMI

March 18, 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

Fish Oils: Yes for HF and Secondary Prevention, No for the General Population, Says AHA

News Daily News

Fish Oils: Yes for HF and Secondary Prevention, No for the General Population, Says AHA

Michael O'Riordan

March 15, 2017

Statin-Intolerant Patients Have Significantly Worse Prognosis After MI

News Daily News

Statin-Intolerant Patients Have Significantly Worse Prognosis After MI

Michael O'Riordan

March 13, 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

March 10, 2017

Erectile Dysfunction Meds Linked to Fewer Death and HF Hospitalizations After MI

News Conference News ACC 2017

Erectile Dysfunction Meds Linked to Fewer Death and HF Hospitalizations After MI

March 09, 2017

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

News Daily News

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

Michael O'Riordan

February 03, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.